Last Updated: July 4, 2026

Patent: 10,231,976

✉ Email this page to a colleague

Summary for Patent: 10,231,976

Title:	Methods for the use of progestogen as a glucocorticoid sensitizer
Abstract:	Provided are methods and kits for administering progestogen as a glucocorticoid sensitizer to restore corticosteroid sensitivity or reverse the glucocorticoid insensitivity or enhance glucocorticoid sensitivity, in order to treat one or more glucocorticoid insensitivity related diseases or conditions. For example, these include methods for reversing the glucocorticoid insensitivity in a subject having no history of menstrual cycle-related exacerbation or allergy to self-hormones, particularly progesterone, such as premenstrual or perimenstrual deterioration in the symptoms, e.g., premenstrual worsening of atopic dermatitis or premenstrual exacerbations of asthma, and exhibiting relatively or totally refractory responses to glucocorticoid therapy, e.g., glucocorticoid resistance. The methods and kits provide for the administration of a sex hormone to the subject who is corticosteroid dependent or corticoid resistant or unresponsive or intolerant to corticosteroids.
Inventor(s):	Du; Tao Tom (North Potomac, MD)
Assignee:	PRAIRIE PHARMACEUTICALS LLC (Bethesda, MD)
Application Number:	13/021,950
Patent Claims:	see list of patent claims

Details for Patent 10,231,976

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998	10,231,976	2031-02-07
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	10,231,976	2031-02-07
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	10,231,976	2031-02-07
Immunex Corporation	ENBREL	etanercept	Injection	103795	September 27, 2004	10,231,976	2031-02-07
Immunex Corporation	ENBREL	etanercept	Injection	103795	February 01, 2007	10,231,976	2031-02-07
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	September 14, 2017	10,231,976	2031-02-07
Immunex Corporation	ENBREL	etanercept	Injection	103795		10,231,976	2031-02-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.